Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in Chronic Migraine (StainMigChronic)
2022-502177-42-01Phase 2Withdrawn
- Sponsor
- St. Olavs University Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of Pensa in chronic migraine (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Change from baseline in number of migraine days per 4 weeks. Planned start Mar 2023; status: withdrawn.
02
Drugs
Pensa
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2022-502177-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502177-42-01.